Cargando…
Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
BACKGROUND: Overall therapeutic outcomes of advanced non-small-cell lung cancer (NSCLC) are poor. The dendritic cell (DC) immunotherapy has been developed as a new strategy for the treatment of lung cancer. The purpose of this study was to evaluate the feasibility, safety and immunologic responses i...
Autores principales: | Perroud, Maurício W, Honma, Helen N, Barbeiro, Aristóteles S, Gilli, Simone CO, Almeida, Maria T, Vassallo, José, Saad, Sara TO, Zambon, Lair |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135553/ https://www.ncbi.nlm.nih.gov/pubmed/21682877 http://dx.doi.org/10.1186/1756-9966-30-65 |
Ejemplares similares
-
Response to cytotoxic chemotherapy and overall survival in non-small cell lung cancer patients with positive or negative ERCC1 expression
por: Honma, Helen Naemi, et al.
Publicado: (2018) -
FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
por: Fiammenghi, Laura, et al.
Publicado: (2010) -
Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
por: Parney, Ian F, et al.
Publicado: (2022) -
Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
por: Sittig, Simone P., et al.
Publicado: (2015) -
The Mechanisms of Human Renal Epithelial Cell Modulation of Autologous Dendritic Cell Phenotype and Function
por: Sampangi, Sandeep, et al.
Publicado: (2015)